Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.

Nature - 1 Jul 2022

Bal Elodie, Kumar Rahul, Hadigol Mohammad, Holmes Antony B, Hilton Laura K, Loh Jui Wan, Dreval Kostiantyn, Wong Jasper C H, Vlasevska Sofija, Corinaldesi Clarissa, Soni Rajesh Kumar, Basso Katia, Morin Ryan D, Khiabanian Hossein, Pasqualucci Laura, Dalla-Favera Riccardo

Abstract excerpt

Diffuse large B cell lymphoma (DLBCL) is the most common B cell non-Hodgkin lymphoma and remains incurable in around 40% of patients. Efforts to sequence the coding genome identified several genes and pathways that are altered in this disease, including potential therapeutic targets1-5. However, the non-coding genome of DLBCL remains largely unexplored. Here we show that active super-enhancers are highly and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer Elements, Genetic
Share to Lymphoma, Large B-Cell, Diffuse

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogenes

Share to Positive Regulatory Domain I-Binding Factor 1

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-bcl-6

Share to Receptors, CXCR4

Share to Receptors, Glucocorticoid

Source

Open in PubMed Open full text

Identifiers

PMID: 35794478
DOI: 10.1038/s41586-022-04906-8
PMCID: PMC9583699

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.PMID 35794478Read ↗

Super-silencers are crucial for development and carcinogenesis in B cellsSemantic proximity Read ↗

A High-Resolution Landscape of Mutations in the <i>BCL6</i> Super-Enhancer in Normal Human B-CellsSemantic proximity Read ↗

Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas.Semantic proximity Read ↗

Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.Semantic proximity Read ↗

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphomaSemantic proximity Read ↗

Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targetsSemantic proximity Read ↗

Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma.Semantic proximity Read ↗

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphomaSemantic proximity Read ↗

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphomaSemantic proximity Read ↗

AID Shapes Proliferation and Cell-of-Origin-associated Transcriptional Programs in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.Semantic proximity Read ↗

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.